BioCryst Pharmaceuticals (BCRX) News Today $11.03 +2.10 (+23.52%) Closing price 04:00 PM EasternExtended Trading$11.04 +0.01 (+0.05%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period BioCryst Pharmaceuticals Reports Record Growth and ProfitabilityMay 5 at 8:26 PM | tipranks.comBioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised InvestorsMay 5 at 6:35 PM | benzinga.comBioCryst Pharmaceuticals (BCRX) Boosts Revenue Guidance on Strong ORLADEYO SalesMay 5 at 4:07 PM | gurufocus.comBioCryst: Strong Opportunity For A Double With A Proven TherapyMay 5 at 2:31 PM | seekingalpha.comBioCryst Pharmaceuticals, Inc. (BCRX) Q1 2025 Earnings Call TranscriptMay 5 at 1:19 PM | seekingalpha.comBioCryst Pharmaceuticals, Inc.: BioCryst Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 5 at 11:13 AM | finanznachrichten.deBioCryst Hikes on Q1 FiguresMay 5 at 11:13 AM | baystreet.caBioCryst Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 5 at 11:13 AM | finance.yahoo.comBioCryst stock jumps on raised guidance, strong Q1 reportMay 5 at 11:13 AM | msn.comBioCryst Pharmaceuticals (BCRX) Surpasses Q1 Expectations, Raises 2025 ForecastMay 5 at 8:08 AM | gurufocus.comBioCryst Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 5 at 7:00 AM | globenewswire.comAquatic Capital Management LLC Sells 80,210 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Aquatic Capital Management LLC lowered its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 58.9% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 55,890 shares of the biotechnology comMay 5 at 4:43 AM | marketbeat.comSusquehanna Fundamental Investments LLC Buys New Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Susquehanna Fundamental Investments LLC purchased a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 88,854 shares of the biotechnology companMay 5 at 4:32 AM | marketbeat.comFirst Trust Advisors LP Sells 28,251 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)First Trust Advisors LP lessened its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 4.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 565,215 shares of the biotechnology company's stocMay 5 at 3:43 AM | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of "Moderate Buy" by AnalystsBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eight brokerages that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and seven have assignMay 5 at 2:15 AM | marketbeat.comCantor Fitzgerald Forecasts BCRX FY2025 EarningsBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for BioCryst Pharmaceuticals in a report released on Tuesday, April 29th. Cantor Fitzgerald analyst S. Seedhouse forecasts that the biotechMay 3 at 8:12 AM | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is Caligan Partners LP's 6th Largest PositionCaligan Partners LP boosted its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 16.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,995,932 shares of the biotechnology company's stock after acquiMay 3 at 7:44 AM | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Voya Investment Management LLCVoya Investment Management LLC reduced its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 29.2% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 625,905 shares of the biotechnology company's stock after selling 257,912 shares during theMay 3 at 4:48 AM | marketbeat.comWells Fargo & Company MN Raises Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Wells Fargo & Company MN lifted its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 53.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 104,163 shares of the biotechnology company's stock after buying an adMay 3 at 3:21 AM | marketbeat.comCantor Fitzgerald Weighs in on BCRX FY2025 EarningsMay 3 at 3:09 AM | americanbankingnews.comBioCryst Pharmaceuticals (BCRX) Projected to Post Earnings on MondayMay 3 at 1:31 AM | americanbankingnews.comBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2 at 7:00 AM | globenewswire.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Coverage Initiated at Cantor FitzgeraldCantor Fitzgerald assumed coverage on BioCryst Pharmaceuticals in a research note on Tuesday. They issued an "overweight" rating and a $20.00 target price for the company.May 1, 2025 | marketbeat.comBioCryst Appoints Steve Frank to Board of DirectorsMay 1, 2025 | globenewswire.comBioCryst to Present at Upcoming Investor ConferencesApril 30, 2025 | globenewswire.comBioCryst Pharmaceuticals (BCRX) Projected to Post Quarterly Earnings on MondayBioCryst Pharmaceuticals (NASDAQ:BCRX) will be releasing its Q1 2025 earnings before the market opens on Monday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-5-biocryst-pharmaceuticals-inc-stock/)April 30, 2025 | marketbeat.comCantor Fitzgerald Initiates Coverage of BioCryst Pharmaceuticals (BCRX) with Overweight RecommendationApril 30, 2025 | msn.comBoothbay Fund Management LLC Grows Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Boothbay Fund Management LLC boosted its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 16.0% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,384,633 shares of the biotechnology company's stock after buying an aApril 28, 2025 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Purchased by Invesco Ltd.Invesco Ltd. boosted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 6.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 1,072,600 shares of the biotechnology company's stock after purchasing an additional 67,492 shares during the perApril 27, 2025 | marketbeat.comEversept Partners LP Has $14.89 Million Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Eversept Partners LP increased its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 269.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,980,312 shares of the biotechnology company's stock after buApril 24, 2025 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Trading 4.7% Higher - Time to Buy?BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Up 4.7% - What's Next?April 23, 2025 | marketbeat.comRock Springs Capital Management LP Cuts Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Rock Springs Capital Management LP lowered its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 26.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,677,996 sharesApril 23, 2025 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Renaissance Technologies LLCRenaissance Technologies LLC lessened its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 7.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 545,021 shares of the biotechnology company's stock after selling 44,059 shares during the quartApril 23, 2025 | marketbeat.comJPMorgan Chase & Co. Has $3.57 Million Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)JPMorgan Chase & Co. reduced its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 17.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 474,376 shares of the biotechnology company's stock after selling 102,753 shares durinApril 22, 2025 | marketbeat.comBioCryst to Report First Quarter 2025 Financial Results on May 5April 21, 2025 | globenewswire.comWedbush Has Bearish Forecast for BCRX FY2025 EarningsBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Equities research analysts at Wedbush dropped their FY2025 EPS estimates for BioCryst Pharmaceuticals in a report issued on Wednesday, April 16th. Wedbush analyst L. Chico now expects that the biotechnology company will earn $0.03 per sApril 19, 2025 | marketbeat.comCapital Fund Management S.A. Reduces Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Capital Fund Management S.A. trimmed its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 83.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 59,327 shares of the biotechnology companApril 19, 2025 | marketbeat.comBank of America Securities Keeps Their Buy Rating on BioCryst (BCRX)April 17, 2025 | markets.businessinsider.comFederated Hermes Inc. Boosts Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Federated Hermes Inc. grew its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 51.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 167,957 shares of the biApril 16, 2025 | marketbeat.comBioCryst Pharmaceuticals' (BCRX) Outperform Rating Reaffirmed at Royal Bank of CanadaRoyal Bank of Canada reaffirmed an "outperform" rating and issued a $11.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday.April 13, 2025 | marketbeat.comNorges Bank Acquires Shares of 524,804 BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Norges Bank bought a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 524,804 shares of the biotechnology company's stock, valued at approximateApril 13, 2025 | marketbeat.comExecutive reshuffles: CVS, NNDM, and DBXApril 12, 2025 | msn.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Given "Buy" Rating at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $15.00 price target on shares of BioCryst Pharmaceuticals in a research note on Thursday.April 12, 2025 | marketbeat.comBioCryst CEO to serve as interim CFOApril 11, 2025 | markets.businessinsider.comBioCryst (BCRX) Gets a Buy from NeedhamApril 10, 2025 | markets.businessinsider.comBioCryst Appoints CEO as Interim CFO Amid TransitionApril 10, 2025 | tipranks.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have been given an average rating of "Moderate Buy" by the seven research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and six have assApril 9, 2025 | marketbeat.comTrexquant Investment LP Reduces Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Trexquant Investment LP lowered its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 43.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 494,356 shares of the biotechnology companyApril 8, 2025 | marketbeat.comVanguard Group Inc. Has $164.62 Million Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Vanguard Group Inc. increased its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 7.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 21,890,422 shares of the biotechnology coApril 8, 2025 | marketbeat.comKLP Kapitalforvaltning AS Takes Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)KLP Kapitalforvaltning AS acquired a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 39,800 shares of the biotechnology company'sApril 8, 2025 | marketbeat.com Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address BCRX Media Mentions By Week BCRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCRX News Sentiment▼0.830.72▲Average Medical News Sentiment BCRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCRX Articles This Week▼286▲BCRX Articles Average Week Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IONS News Today ALKS News Today FOLD News Today LGND News Today MNKD News Today CLDX News Today DVAX News Today INVA News Today NVAX News Today OPK News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCRX) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BCRX Stock Free BCRX Stock Alerts